$ACAD News

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35

Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36

Acadia Pharmaceuticals Gets EMA CHMP Positive Opinion Recommending DAYBU Marketing Authorization For Rett Syndrome

Acadia Pharmaceuticals: The Song Remains The Same

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness

Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts

What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Q1 Earnings Call Highlights

Acadia (ACAD) Q1 2026 Earnings Transcript

ACADIA Pharmaceuticals Inc. 2026 Q1 - Results - Earnings Call Presentation